PLANO, Texas, Jan. 3, 2024 /PRNewswire/ — AnX Robotica, a pioneering force in advanced gastrointestinal visualization technologies, is excited to announce the FDA clearance of NaviCam ProScan™. Through the rigorous De Novo Submission Process, the FDA has granted clearance for ProScan, making it the first AI Assisted Reading Tool designed to aid small bowel capsule… Continue reading AnX Robotica Announces FDA Clearance for ProScan™: A Groundbreaking AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy
Category: Newswire
Pomvom Ltd. and Israel Acquisitions Corp. Announce Definitive Business Combination Agreement, Bringing the Leading Experiential Content Company to the Nasdaq
TEL-AVIV, Israel, Jan. 2, 2024 /PRNewswire/ — Israel Acquisitions Corp. (NASDAQ: ISRL) (NASDAQ: ISRLU) (NASDAQ: ISRLW) (“ISRL”) , a publicly-traded special purpose acquisition company, and Pomvom Ltd.(TASE: PMVM) (“Pomvom” or the “Company”), a technology company that develops experiential content to amusement parks and attractions globally, replacing operative physical solutions, today announced a definitive business combination… Continue reading Pomvom Ltd. and Israel Acquisitions Corp. Announce Definitive Business Combination Agreement, Bringing the Leading Experiential Content Company to the Nasdaq
Thailand welcome 2024 at CentralWorld, Times Square of Asia – The only one World’s Entertainment Countdown Landmark of All Time in the Heart of Bangkok
BANGKOK, Jan. 2, 2024 /PRNewswire/ — Central Pattana plc, Thailand’s number one real estate developer and operator of 39 Central shopping centers nationwide, in collaboration with leading public and private partners including the Tourism Authority of Thailand, Bangkok Metropolitan Administration Royal Thai Police and Ratchaprasong Square Trade Association (RSTA), etc., created a sensational world-class countdown event,… Continue reading Thailand welcome 2024 at CentralWorld, Times Square of Asia – The only one World’s Entertainment Countdown Landmark of All Time in the Heart of Bangkok
Harnessing the Transformative Power of Cold Chain Logistics with SSI Schaefer
SINGAPORE and DUBAI, UAE and RIYADH, Saudi Arabia, Jan. 2, 2024 /PRNewswire/ — As average global temperatures rise and the demand for cold-chain storage grows worldwide, SSI Schaefer, a global leader in intralogistics and automated warehouses, is sharing best practices and key considerations on how logistics and operations managers can optimize efficiency and cost-effectiveness of… Continue reading Harnessing the Transformative Power of Cold Chain Logistics with SSI Schaefer
Itchko and Misha Ezratti’s GL Homes Donates Over $100,000 & Gives Back for the Holidays
SUNRISE, Fla., Jan. 2, 2024 /PRNewswire/ — In the true spirit of giving, GL Homes took the lead as the title sponsor of five Boys & Girls Clubs holiday gift drives throughout Florida and has donated more than $100,000 towards the cause this holiday season. Thousands of children and teens in Collier, Lee, Palm Beach,… Continue reading Itchko and Misha Ezratti’s GL Homes Donates Over $100,000 & Gives Back for the Holidays
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Brooge Energy Limited Investors to Inquire About Securities Class Action Investigation – BROG
NEW YORK, Jan. 2, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Brooge Energy Limited (NASDAQ: BROG) resulting from allegations that Brooge may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Brooge securities you… Continue reading ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Brooge Energy Limited Investors to Inquire About Securities Class Action Investigation – BROG
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action – ILMN
NEW YORK, Jan. 2, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Illumina, Inc. (NASDAQ: ILMN) between May 1, 2023 and October 16, 2023, both dates inclusive (the “Class Period”), of the important January 9, 2024 lead plaintiff deadline. SO WHAT: If you purchased Illumina securities… Continue reading ROSEN, NATIONAL TRIAL COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action – ILMN
ROSEN, A TOP RANKED LAW FIRM, Encourages General Motors Company Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – GM
NEW YORK, Jan. 2, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of General Motors Company (NYSE: GM) between February 2, 2022 and October 26, 2023, both dates inclusive (the “Class Period”), of the February 6, 2024 lead plaintiff deadline. SO WHAT: If you purchased GM securities… Continue reading ROSEN, A TOP RANKED LAW FIRM, Encourages General Motors Company Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – GM
Klaytn Onboards Goldstation and $GPC, Launching the First Gold RWA DeFi Platform Outside of Ethereum
Goldstation, the first-ever gold DeFi platform on a public mainnet outside of Ethereum, combines Klaytn’s low fees and latency to offer more efficient gold investments through $GPC, a gold-pegged token 1:1 backed by physical gold. South Korean residents will be able to convert their physical gold holdings into NFTs via The Mining Club, then using… Continue reading Klaytn Onboards Goldstation and $GPC, Launching the First Gold RWA DeFi Platform Outside of Ethereum
Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China
Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c reductions of 1.96 and 2.43% from baseline, respectively, compared to 0.87 % for placebo In the 1.2 mg ecnoglutide cohort, 76.1% of participants achieved HbA1c ≤ 6.5% and 35.2% achieved HbA1c < 5.7% at the end of the 24-week treatment Ecnoglutide was safe… Continue reading Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China